GRI Bio, Inc. (GRI)
NASDAQ: GRI · IEX Real-Time Price · USD
0.760
-0.016 (-2.06%)
At close: Mar 28, 2024, 4:00 PM
0.771
+0.011 (1.43%)
After-hours: Mar 28, 2024, 6:47 PM EDT
Company Description
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States.
Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder.
GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Bio, Inc.
Country | United States |
Founded | 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Dr. W. Marc Hertz Ph.D. |
Contact Details
Address: 2223 Avenida De La Playa, Suite 208 La Jolla, California 92037 United States | |
Phone | (619) 400-1171 |
Website | gribio.com |
Stock Details
Ticker Symbol | GRI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001824293 |
ISIN Number | US3622AW2059 |
Employer ID | 82-4369909 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. W. Marc Hertz Ph.D. | Co-Founder, Chief Executive Officer, President and Director |
Leanne M. Kelly | Chief Financial Officer and Corporate Secretary |
Dr. Vipin Kumar Chaturvedi Ph.D. | Co-Founder and Chief Scientific Officer |
Dr. Albert Agro Ph.d. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | 424B3 | Prospectus |
Mar 28, 2024 | 424B3 | Prospectus |
Mar 28, 2024 | 10-K | Annual Report |
Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 2, 2024 | 424B3 | Prospectus |
Feb 2, 2024 | 8-K | Current Report |
Feb 2, 2024 | 424B4 | Prospectus |
Feb 1, 2024 | EFFECT | Notice of Effectiveness |
Jan 31, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Jan 31, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |